Zai Lab to present first global data on DLL3 ADC zocilurtatug pelitecan in first-line ES-SCLC trial at ESMO 2026

By Public Technologies
  • Zai Lab flagged first global results from a trial of zocilurtatug pelitecan for first-line extensive-stage small cell lung cancer.
  • Data have not been released yet; an ESMO Congress 2026 poster is scheduled for Oct. 26 in Madrid.
  • The study tests the DLL3-targeting antibody-drug conjugate with atezolizumab, with or without carboplatin.
  • Zai Lab framed the readout as supportive of zocilurtatug pelitecan as a potential backbone therapy in first-line combinations.
  • An investor call is set for Oct. 23 to discuss the ESMO presentation and the program’s next clinical steps.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zai Lab Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 202609290700BIZWIRE_USPR_____20260929_BW210432) on September 29, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk